Nektar Rebounds on Drug Data After 7.77% Drop From Prior Trial Failure

Edgen Stock·Mar 28 2026, 16:51

Share to

Share to

Copy link

Key Takeaways

Nektar Therapeutics presented positive Phase 2b trial results for its atopic dermatitis drug, Rezpegaldesleukin, offering a potential path forward after a separate trial failure in late 2025 damaged investor confidence and triggered a class-action lawsuit. The new data, revealed at a major dermatology conference, positions the company to advance a key asset, but it enters an increasingly competitive market.

Nektar's Rezpegaldesleukin showed statistically significant improvement in patients with moderate-to-severe atopic dermatitis in a Phase 2b study.
The positive news follows a December 16, 2025, announcement of a failed trial in alopecia areata, which caused Nektar's stock to drop 7.77% to $49.16 in a single day.
The atopic dermatitis market is highly competitive, with rivals like Aclaris and Kymera also presenting strong trial data at the same medical conference.

Rezpegaldesleukin Scores Key Win in Atopic Dermatitis Trial

Nektar Therapeutics (NASDAQ: NKTR) presented statistically significant positive data from its Phase 2b REZOLVE-AD study for Rezpegaldesleukin on March 28, 2026. The results, unveiled at the American Academy of Dermatology Annual Meeting, showed the drug produced a meaningful improvement in patients with moderate-to-severe atopic dermatitis. This successful outcome across 393 patients provides a critical validation for Nektar's lead product candidate and de-risks its path toward potential Phase 3 trials.

Data Offers Path to Recovery After 7.77% Stock Plunge

The positive dermatitis data contrasts sharply with a significant setback from late 2025. On December 16, 2025, Nektar announced its Phase 2b trial for the same drug in alopecia areata (REZOLVE-AA) failed to meet its primary endpoint. The company attributed the failure to the inclusion of four ineligible patients, but the news triggered a sharp investor sell-off. Nektar's stock price fell 7.77%, or $4.14 per share, to close at $49.16 that day. The event led to the filing of a class-action lawsuit alleging the company had previously overstated the trial's integrity and prospects, creating a legal overhang that the new positive data may help offset.

Crowded Field Heats Up with Rival Drug Data

While Nektar's results are promising, the company is advancing its drug in a highly competitive therapeutic area. The same dermatology conference featured strong results from rivals. Aclaris Therapeutics reported its drug, ATI-2138, achieved a 77% improvement on the Eczema Area and Severity Index (EASI) in a Phase 2a trial. Meanwhile, Kymera Therapeutics presented data for its oral drug, KT-621, which demonstrated a 63% reduction in EASI in its Phase 1b trial. This competitive pressure means Nektar must not only succeed clinically but also differentiate Rezpegaldesleukin to capture market share.